New ultrasound technique could spot cancer in lymph nodes without a needle
NCT ID NCT07155954
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new type of ultrasound called super-resolution ultrasound (SRUS) to see if it can better tell the difference between benign (non-cancerous) and malignant (cancerous) swollen lymph nodes. About 779 adults with abnormal lymph nodes will receive an injection of ultrasound contrast agent, and the movement of tiny bubbles will be tracked to create a detailed map of blood vessels. The goal is to improve diagnostic accuracy and potentially reduce the need for invasive biopsies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ultrasound contrast agent (Sonovue or Sonazoid)
- What this could lead to
- If successful, this could give doctors a more accurate, non-invasive way to tell if swollen lymph nodes are cancerous or not, reducing unnecessary biopsies.
- What could go wrong
- This is an early-stage diagnostic study, not a treatment. The technique may not prove more accurate than current methods, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 779 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with abnormal lymph nodes and who are scheduled for lymph nodes puncture or fine needle aspiration or surgery
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * (1)suggested abnormal lymph nodes indicated by ultrasonography; (2) Patients scheduled for lymph nodes puncture or fine needle aspiration or surgery; (3) Age greater than or equal to 18 years old. Exclusion Criteria: * (1) Pregnant and lactating women; (2)pathological results not indicating benign or malignant lymph nodes; (3) history of chemotherapy or radiotherapy ; (4) History of allergies to eggs, milk, and ultrasound contrast agents; (5) Patients with acute coronary syndrome, severe pulmonary hypertension, or acute respiratory distress syndrome.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lymphadenopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100049, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Reprogrammed immune cells target CD30-Positive lymphoma in early trial
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- Double-Drug attack on Hard-to-Treat lymphomas
- Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
- Can a calming drug make cord blood transplants safer?